| Bucks County Geriatrics Llc | |
|
240 Middletown Blvd Ste 101c Langhorne PA 19047-1832 | |
| (865) 439-0121 | |
| Not Available |
| Full Name | Bucks County Geriatrics Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 240 Middletown Blvd Ste 101c, Langhorne, Pennsylvania |
| Authorized Official Name and Position | Michelle Scannapieco (OWNER) |
| Authorized Official Contact | 8654190121 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Bucks County Geriatrics Llc Po Box 207 Langhorne PA 19047-0207 Ph: () - | Bucks County Geriatrics Llc 240 Middletown Blvd Ste 101c Langhorne PA 19047-1832 Ph: (865) 439-0121 |
| NPI Number | 1104305770 |
|---|---|
| Provider Enumeration Date | 08/14/2018 |
| Last Update Date | 04/01/2020 |
| Medicare PECOS PAC ID | 3375888779 |
|---|---|
| Medicare Enrollment ID | O20181212002924 |
News Archive
Modern Healthcare: As part of the new health law, HHS is distributing $68 million in grants "to help people navigate their health and long-term-care options. The grants will be going to states, territories, tribal and community-based organizations to help seniors, individuals with disabilities and caregivers make more-informed decisions about their health and long-term care.
Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.
First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.
The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104305770 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | (* (Not Available)) | Primary |
| Provider Name | Kathleen Hill Oneill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497950869 PECOS PAC ID: 8123129327 Enrollment ID: I20070718000239 |
News Archive
Modern Healthcare: As part of the new health law, HHS is distributing $68 million in grants "to help people navigate their health and long-term-care options. The grants will be going to states, territories, tribal and community-based organizations to help seniors, individuals with disabilities and caregivers make more-informed decisions about their health and long-term care.
Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.
First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.
The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.
› Verified 7 days ago
| Provider Name | Sherry L Shire-misnik |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770721433 PECOS PAC ID: 9133121858 Enrollment ID: I20090326000032 |
News Archive
Modern Healthcare: As part of the new health law, HHS is distributing $68 million in grants "to help people navigate their health and long-term-care options. The grants will be going to states, territories, tribal and community-based organizations to help seniors, individuals with disabilities and caregivers make more-informed decisions about their health and long-term care.
Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.
First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.
The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.
› Verified 7 days ago
| Provider Name | Michelle A Scannapieco |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1386792398 PECOS PAC ID: 4284814518 Enrollment ID: I20110203000730 |
News Archive
Modern Healthcare: As part of the new health law, HHS is distributing $68 million in grants "to help people navigate their health and long-term-care options. The grants will be going to states, territories, tribal and community-based organizations to help seniors, individuals with disabilities and caregivers make more-informed decisions about their health and long-term care.
Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.
First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.
The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.
› Verified 7 days ago
| Provider Name | Maryann B Phinney |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558414979 PECOS PAC ID: 4082784178 Enrollment ID: I20150618001313 |
News Archive
Modern Healthcare: As part of the new health law, HHS is distributing $68 million in grants "to help people navigate their health and long-term-care options. The grants will be going to states, territories, tribal and community-based organizations to help seniors, individuals with disabilities and caregivers make more-informed decisions about their health and long-term care.
Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.
First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.
The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.
› Verified 7 days ago
News Archive
Modern Healthcare: As part of the new health law, HHS is distributing $68 million in grants "to help people navigate their health and long-term-care options. The grants will be going to states, territories, tribal and community-based organizations to help seniors, individuals with disabilities and caregivers make more-informed decisions about their health and long-term care.
Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.
First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.
The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.
› Verified 7 days ago
Aria Oxford Valley Medical Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 320 Middletown Blvd, Suite 301, Langhorne, PA 19047 Phone: 215-757-5400 Fax: 215-750-2611 | |
The Bariatric And Metabolic Surgery Program At St.mary Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1205 Langhrn Nwtwn Rd Ste 310, Langhorne, PA 19047 Phone: 215-710-5711 Fax: 215-710-5925 | |
Oxygen Oasis Hyperbaric Wellness Center, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 848 Town Center Dr, Langhorne, PA 19047 Phone: 215-603-8225 | |
Bucks County Geriatrics Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1205 Langhrn Nwtwn Rd Ste 102, Langhorne, PA 19047 Phone: 215-710-4480 Fax: 215-710-4485 | |
Thma Mg Endocrinology Langhorne Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1205 Langhorne Newtown Rd Ste 302, Langhorne, PA 19047 Phone: 215-710-5212 Fax: 215-710-5213 | |
Luxembourg Medical Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 508 Corporate Dr W, Luxembourg Corporate Center, Langhorne, PA 19047 Phone: 215-860-4380 Fax: 215-968-5918 | |
Comprehensive Metabolism And Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1205 Newtown Langhorne Road Suite 406, St Mary Medical Office, Langhorne, PA 19047 Phone: 215-630-1361 Fax: 215-550-6115 |